In a phase 3 trial, Kisqali reduced the risk of patients’ breast cancer coming back by 25% after three years when given in addition to other standard treatments, according to a Sept. 17 news release from Novartis, the drug’s manufacturer.
After four years, Kisqali also helped reduce the risk by 28.5%, according to a recent analysis presented at the European Society of Medical Oncology conference, Novartis said in a Sept. 16 news release.
Until Kisqali, only breast cancer drug Verzenio was approved to reduce the risk of patients with early breast cancer, although it was available only to patients with a very high risk of recurrence, NBC News reported Sept. 17.
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
